Management of climacteric syndrome
DOI:
https://doi.org/10.33448/rsd-v14i6.49059Keywords:
Diagnosis, Clinical evaluation, Treatment, Climacteric, Menopause.Abstract
The aim of the present study was to identify the main strategies for managing the symptoms of climacteric syndrome in women. A narrative review of the literature was conducted according to the recommendations of the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guideline, with studies available in the PubMed database. Only articles published in English or Portuguese, from January 2014 onwards, with experimental or observational design, and populations consisting of women in the climacteric who had received some treatment for climacteric syndrome were included. The diagnosis of climacteric and menopause is clinical and can be complemented by the measurement of follicle-stimulating and luteinizing hormones. The best treatment for vasomotor symptoms is combined and systemic hormone replacement therapy, which is also effective for most symptoms of climacteric syndrome, including genitourinary symptoms, mood and sleep disorders, bone loss and arthralgias. Transdermal hormone therapy is a safe, effective alternative that offers fewer adverse effects than systemic therapy. Isolated genitourinary symptoms can be treated with vaginal estrogen, an option with a good safety and effectiveness profile, or with alternative therapies, including topical prasterone, oral ospemifene, vaginal hyaluronic acid, vaginal lubricants and moisturizers. Climacteric depression is a disorder of endocrine etiology, so hormone replacement therapy offers more satisfactory results than treatment with antidepressants and psychotropic drugs. This review summarized the most recent evidence on the management of climacteric syndrome, presenting effective and safe therapeutic modalities for most patients.
Downloads
References
Agrawal, S. et al. (2024). A randomized, pilot trial comparing vaginal hyaluronic acid to vaginal estrogen for the treatment of genitourinary syndrome of menopause. Menopause. 31(9), 750-5. https://doi.org/10.1097/GME.0000000000002390.
Alperin, M. et al. (2019). The mysteries of menopause and urogynecologic health. Menopause. 26(1), 103-11. https://doi.org/10.1097/gme.0000000000001209.
Baccaro, L. F. C. et al. (2022). Initial evaluation in the climacteric. Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics. 44(5), 548-56. https://doi.org/10.1055/s-0042-1750282.
Botelho, L. L. R., Cunha, C. C. A. & Macedo, M. (2011). O método da revisão integrativa nos estudos organizacionais. Gestão E Sociedade, Belo Horizonte-MG.121-136. https://doi.org/10.21171/ges.v5i11.1220.
Chen, F-P. et al. (2016). Efficacy of Femarelle for the treatment of climacteric syndrome in postmenopausal women: an open label trial. Taiwanese Journal of Obstetrics and Gynecology. 55(3), 336-40. https://doi.org/10.1016/j.tjog.2016.04.008.
Crossetti, M. G. M. (2012). Revisión integradora de la investigación en enfermería el rigor científico que se le exige. Maria Da Graça Oliveira Crossetti. Rev. Gaúcha Enferm. 33 (2): 8-9. Curta, J. C. & Weissheimer, A. M. (2020). Perceptions and feelings about physical changes in climacteric women. Revista Gaúcha de Enfermagem. 41 (spe). https://doi.org/10.1590/1983-1447.2020.20190198.
Dyk, K. V. & Carroll, J. E. (2024). Shining a spotlight on sleep disturbance related cognitive impairment and relevance to menopause. SLEEP. https://doi.org/10.1093/sleep/zsae136.
Guerra, G. E. S. et al. (2019). Quality of life in climacteric women assisted by primary health care. PLOS ONE. 14(2), e0211617. https://doi.org/10.1371/journal.pone.0211617.
Kagan, R., Kellogg-Spadt, S. & Parish, S. J. (2019). Practical treatment considerations in the management of genitourinary syndrome of menopause. Drugs & Aging. 36 (10), 897-908. https://doi.org/10.1007/s40266-019-00700-w.
Kingsberg, S. et al. (2024). Real-world evaluation of treatment utilization by women experiencing vasomotor symptoms associated with menopause in the United States and Europe: Findings from the REALISE study. Maturitas, p. 108096. https://doi.org/10.1016/j.maturitas.2024.108096.
Leite, R. R. et al. (2022). Clustering of behavioral risk factors for chronic noncommunicable diseases in climacteric women. Einstein (São Paulo). 20. https://doi.org/10.31744/einstein_journal/2022ao6153.
Acesso em: 1 nov. 2024. Marlatt, K. L. et al. (2021). Body composition and cardiometabolic health across the menopause transition. Obesity. 30(1), 14-27. https://doi.org/10.1002/oby.23289.
Nair, A. R., Pillai, A. J. & Nair, N. (2020). Cardiovascular changes in menopause. Current Cardiology Reviews. 16. https://doi.org/10.2174/1573403x16666201106141811.
Nappi, R. E. et al. (2021). Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden. Menopause. 28 (8), 875-82. https://doi.org/10.1097/gme.0000000000001793.
Nelson, S. M. et al. (2023). Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review. Human Reproduction Update. 29(3), 327-46. https://doi.org/10.1093/humupd/dmac045.
Page, M. J. et al. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Journal of Clinical Epidemiology. 134, 178-89. https://doi.org/10.1016/j.jclinepi.2021.03.001.
Acesso em: 17 jan. 2024. Pereira A. S. et al. (2018). Metodologia da pesquisa científica. [free e-book]. Santa Maria/RS. Ed. UAB/NTE/UFSM. Salari, Nader et al. (2023). Global prevalence of sleep disorders during menopause: a meta-analysis. Sleep and Breathing. https://doi.org/10.1007/s11325-023-02793-5.
Sarri, G. et al. (2017). Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause. BJOG: An International Journal of Obstetrics & Gynaecology. 124(10), 1514-23. https://doi.org/10.1111/1471-0528.14619.
Scavello et al. (2019). Sexual health in menopause. Medicina. 55(9), 559. https://doi.org/10.3390/medicina55090559.
Shapiro, C. M. et al. (2024). Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopause. Maturitas. 107999. https://doi.org/10.1016/j.maturitas.2024.107999.
Snyder, H. (2019). Literature review as a research methodology: An overview and guidelines. Journal of business research, 104, 333-339. Sorpreso, I. C. E. et al. (2020). Diagnosis and referral flow in the single health system for climacteric women. Revista da Associação Médica Brasileira. 66(8), 1036-42. Disponível em: https://doi.org/10.1590/1806-9282.66.8.1036.
Sorpreso, I. C. E. et al. (2021). Brazilian National Policy of Comprehensive Women’s Health Care and mortality during climacteric period: has anything changed? BMC Public Health. 21(1). https://doi.org/10.1186/s12889-021-10556-8.
Stuenkel, C. A. et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 100(11), 3975-4011, nov. 2015. Disponível em: https://doi.org/10.1210/jc.2015-2236.
Ward, E. et al. (2018). Patterns of cardiometabolic health as midlife women transition to menopause: a prospective multiethnic study. The Journal of Clinical Endocrinology & Metabolism. 104(5), 1404-12. https://doi.org/10.1210/jc.2018-00941.
Wild, R. A. et al. (2021). Cardiovascular disease (CVD) risk scores, age, or years since menopause to predict cardiovascular disease in the Women's Health Initiative. Menopause. 28(6), 610-8. https://doi.org/10.1097/gme.0000000000001753.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Isabella Cavallo; Maria Lucia Fim Rodrigues; Mateus Ramos Rodrigues; Luiz Gustavo Peron Martins
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
